Reviva Pharmaceuticals Holdings Inc.

Reviva Pharmaceuticals Holdings Inc. a clinical-stage biopharmaceutical company discovers develops and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system respiratory cardiovascular metabolic and inflammatory diseases. The company's lead product candidate is brilaroxazine (RP5063) which is in Phase III clinical trials for the treatment of schizophrenia as well as completed Phase I clinical trials to treat bipolar disorder major depressive disorder attention"deficit/hyperactivity disorder behavioral and psychotic symptoms of dementia or Alzheimer's disease Parkinson's disease psychosis attention deficit hyperactivity disorder pulmonary arterial hypertension and idiopathic pulmonary fibrosis. It is also developing RP1208 that is in pre-clinical development studies for the treatment of depression and obesity. The company is based in Cupertino California."